Evercore ISI analyst Umer Raffat downgraded Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) from Outperform to In Line.The analyst comments "Amylyx failed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE